• Biomolecules & Therapeutics
• /
• v.6 no.4
• /
• pp.412-416
• /
• 1998

Acute oral toxicity of Bifidobacterium breve K-110, Bifidobacterium breve K-111, Bifidobacterium infantis K-525 were studied in Sprague-Dawley rats of both sexes. In this study, we examined number of deaths, clinical signs, bod weight and gross findings for 14 day after single oral administration of B. breve K-110,B. breve K-111 or B. infantis K-525 with different levels. They did not show any toxic effect in rats and oral LD$_{50}$ value was over 5 g/kg in rats.s.

• Korean Journal of Food Science and Technology
• /
• v.31 no.2
• /
• pp.547-552
• /
• 1999

Antidiarrheal, anticostive and antimutagenic effects of Bifidobacterium breve K-110, K-111 and B. infantis K-525 isolated from Korean were investigated in experimental animals. These Bifidobacteria were not significantly affected on the transport of barium sulfate in the small intestine. However, these Bifidobacteria significantly stimulated the transport of barium sulfate in the large intestine. Particularly, when Bifidobacterium breve K-110 (500 mg/kg) was orally administered, the transport of barium sulfate in the large intestine was increased 45%, compared to the control group. On the castor oil-induced diarrheal mice, Bifidobacterium breve K-111 had the antidiarrheal activity but the other Bifidobacteria did not had it. When the antimutagenicity of these Bifidobacteria and their peptidoglycans were examined using Salmonella typhimurium TA98/TA100 in an in vitro assay system, these Bifidobacteria and peptidoglycans showed inhibitory effect of $20{\sim}80%$. These results indicate that Bifidobacterium spp. had antidiarrheal, anticostive and antimutagenic activities as well as the inhibitory activity of harmful enzymes of intestinal bacteria in the intestine.

• YAKHAK HOEJI
• /
• v.42 no.6
• /
• pp.639-641
• /
• 1998

Minimal inhibitory concentrations (MICs) of Bifidobacterium spp. strains (Bifidobacterium breve K-110, B. breve K-111 and B. infantis K-525) isolated from healthy Korean against antituberculosis agents and fluoroquinolones were determined. From the MICs it was found that Bifidobacterium breve K-110, B. breve K-111 and B. infantis K-525 were susceptible to rifampicin and fluoroquinolenes and resistant to other antituberculosis agents.

• Korean Journal of Food Science and Technology
• /
• v.31 no.4
• /
• pp.1096-1100
• /
• 1999

The protective effect of Bifidobacterium breve K-110, K-111 and B. infantis K-525 on carbon tetrachloride induced hepatotoxicity in rats was investigated. Among them, B. infantis K-525 had the most potent hepatoprotective activity. It reduced serum aspartate aminotransferase and alanine aminotransferase levels to 51% and 80% of the $CCl_{4}-treated$ groups, respectively. In rat liver homogenate intoxificated with $CCl_{4}$, B. infantis K-525 inhibited in vitro as well as in vivo lipid peroxidation more than the other Bifidobacteria.

• Journal of Microbiology and Biotechnology
• /
• v.9 no.3
• /
• pp.368-370
• /
• 1999

The protective role of Bifidobacterium spp. (B. breve K-110, B. breve K-111, and B. infantis K-525) isolated from the fecal samples of healthy Koreans was investigated on 1,2-dimethylhydrazine (DMH)-induced aberrant crypt foci(ACF) formation in mouse colon. In mice fed normal diet with DMH treatment, an average of 68.5 ACF/colon was formed, whereas in mice administered with B. breve K-110, B. breve K-111, and B. infantis K-525, the numbers of DMH-induced ACF decreased to 7.2, 10.9, and 6.6 ACF/ colon, respectively. The mean number of crypts/focus was not significantly altered. Fecal harmful enzymes, such as β-glucuronidase, tryptophanase, and urease, were effectively inhibited during the administration of these bifidobacteria to mice. These results suggest that bifidobacteria could prevent colon cancer.

• Journal of Microbiology and Biotechnology
• /
• v.12 no.4
• /
• pp.553-556
• /
• 2002

The inhibitory activity of fifty Bifidobacteria toward the infectivity of a rotavirus, which is the predominant cause of sporadic diarrhea in infants and young children, was investigated, and Bifidobacterium breve K-110 was found to have the most potent inhibitory activity. Accordingly, the rotavirus infection-inhibitory protein was purified, and its molecular weight was determined to be 76 kDa by SDS-PAGE. It was heat-labile and its 50% inhibitory concentration ($IC_{50}$) was 0.045 $\mu g/ml$.

• Archives of Pharmacal Research
• /
• v.25 no.5
• /
• pp.681-684
• /
• 2002

This study was undertaken to investigate the hypocholesterolemic activity of Bifidobacteria (B. breve K-110, B. breve K-111, and B. infantis K-525) isolated from a healthy Korean. The administration of B. breve K-110 and K-111 with a high cholesterol diet significantly protected the increase of serum total cholesterol and LDL cholesterol relative to that of a high cholesterol diet alone. Such a diet supplemented with 0.5％ B. breve K-111 decreased serum total cholesterol and LDL cholesterol to 57 and 55％, respectively. The administration of Bifidobacteria also significantly inhibited the lipid-deposited surface in the aorta. The normalizing activity of serum cholesterol level in cholesterolemic rats was accelerated by Bifidobacteria. The normalizing activity of B. breve K-111 on serum cholesterol level was superior to that of B. breve K-110. These results suggest that Bifidobacteria in the human intestine playa role in the prophylactics of arteriosclerosis.

• Proceedings of the PSK Conference
• /
• 2002.10a
• /
• pp.333.2-333.2
• /
• 2002

Kakkalide from Puerariae Flos expresses pharmacological actions after biotransformation to irisolidone by intestinal bacteria. B. breve K-110 was isolated as a bacterium metabolizing kakkalide. Therefore. we purified kakkalide-metabolizing p-Xylosidase from B. breve K-110. ${\beta}$-Xylosidase from B. breve K-110 (isolated from Korean intestinal microflora) was induced by kakkalide. We used defined medium contating 1mM kakkalide for the cultivationof B. breve K-110. (omitted)

• Journal of Microbiology and Biotechnology
• /
• v.22 no.4
• /
• pp.535-540
• /
• 2012

${\beta}$-D-Xylosidase (E.C. 3.2.1.37) from Bifidobacterium breve K-110, which hydrolyzes ginsenoside Ra1 to ginsenoside Rb2, was cloned and expressed in Escherichia coli. The ($His_6$)-tagged recombinant enzyme, designated as XlyBK-110, was efficiently purified using $Ni^{2+}$-affinity chromatography (109.9-fold, 84% yield). The molecular mass of XylBK-100 was found to be 55.7 kDa by SDS-PAGE. Its sequence revealed a 1,347 bp open reading frame (ORF) encoding a protein containing 448 amino acids, which showed 82% identity (DNA) to the previously reported glycosyl hydrolase family 30 of Bifidobacterium adolescentis ATCC 15703. The $K_m$ and $V_{max}$ values toward p-nitrophenyl-${\beta}$-D-xylopyranoside (pNPX) were 1.45mM and 10.75 ${\mu}mol/min/mg$, respectively. This enzyme had pH and temperature optima at 6.0 and $45^{\circ}C$, respectively. XylBK-110 acted to the greatest extent on xyloglucosyl kakkalide, followed by pNPX and ginsenoside Ra1, but did not act on p-nitrophenyl-${\alpha}$-L-arabinofuranoside, p-nitrophenyl-${\beta}$-D-glucopyranoside, or p-nitrophenyl-${\beta}$-D-fucopyranoside. In conclusion, this is the first report on the cloning and expression of ${\beta}$-D-xylosidase-hydrolyzing ginsenoside Ra1 and kakkalide from human intestinal microflora.

• Archives of Pharmacal Research
• /
• v.21 no.1
• /
• pp.54-61
• /
• 1998

Five hundreds of bifidobacteria were isolated from a healthy Korean and the inhibitory effects of these isloated bacteria on harmful enzymes of human intestinal microflora were examined by cocultivation of the isolated bifidobacteria with E. coli or total human intestinal microflora. In comparison with the results of E. coli or intestinal microflora cultivation, Bifidobacterium breve K-110, B. breve K-111 and B. infantis K-525 effectively inhibited harmful enzymes ($\beta$-glucuronidase and tryptophanase) of E. coli and lowered the pH of the culture media. Also they inhibited the harmful enzymes ($\beta$-glucosidase, $\beta$-glucuronidase, tryptophanase and urease) and ammonia production of intestinal microflora, and lowered pH of the culture media by increasing lactic acid bacteria of intestinal microflora. When these isolated bifidobacteria were administered on mice, fecal harmful enzymes were also inhibited. Among tested bifidobacteria, B. breve K-110 had the highest inhibitory effect of fecal harmful enzymes.